Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: The linkage among cell biology, pathology and translational research

American Journal of Translational Research

Volumn 3, Issue 2, 2011, Pages 149-158

  Mannello, Ferdinando ^a   Raffetto, Joseph D ^b,c  

^a UNIVERSITY OF URBINO   (Italy)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chronic venous disease; Dermatan sulphate; Fibroblast; Glycosaminoglycan; Inflammation; Leukocyte; Matrix metalloproteinase; Tissue inhibitor of MMP; Varicose vein; Venous ulcer

Indexed keywords

CHONDROITIN 4 SULFATE; CHONDROITIN 6 SULFATE; COLLAGEN; DERMATAN SULFATE; ELASTIN; FIBRONECTIN; GELATINASE B; GLYCOSAMINOGLYCAN; GROWTH FACTOR; MATRIX METALLOPROTEINASE; PROTEOGLYCAN; SULODEXIDE; TISSUE INHIBITOR OF METALLOPROTEINASE;

CHRONIC VEIN INSUFFICIENCY; COMPRESSION BANDAGE; CYTOLOGY; CYTOPATHOLOGY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; LEG ULCER; MORBIDITY; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; THROMBOPHLEBITIS; TRANSLATIONAL RESEARCH; ULCER HEALING; VARICOSIS; VEIN VALVE; VEIN WALL;

EID: 79952928710     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Meissner MH, Gloviczki P, Bergan J, Kistner RL, Morrison N, Pannier F, Pappas PJ, Rabe E, Raju S, and Villavicencio JL. Primary chronic venous disorders. J Vasc Surg 2007; 46 Suppl S: 54S-67S.
2. Raffetto JD and Khalil RA. Mechanisms of varicose vein formation: valve dysfunction and wall dilation. Phlebology 2008; 23(2): 85-98.
3. Bergan JJ, Schmid-Schonbein GW, Smith PD, Nicolaides AN, Boisseau MR, and Eklof B. Chronic venous disease. N Engl J Med 2006; 355(5): 488-498.
4. Nicolaides AN. Chronic venous disease and the leukocyte-endothelium interaction: from symptoms to ulceration. Angiology 2005; 56 Suppl 1: S11-S19.
5. Raffetto JD. Dermal pathology, cellular biology, and inflammation in chronic venous disease. Thromb Res 2009; 123 Suppl 4: S66-S71.
6. Moore K, Huddleston E, Stacey MC, and Harding KG. Venous leg ulcers-the search for a prognostic indicator. Int Wound J 2007; 4(2): 163-172.
7. Meissner MH, Eklof B, Smith PC, Dalsing MC, DePalma RG, Gloviczki P, Moneta G, Neglen P, O' DT, Partsch H, and Raju S. Secondary chronic venous disorders. J Vasc Surg 2007; 46 Suppl S: 68S-83S.
8. Fiebig A, Krusche P, Wolf A, Krawczak M, Timm B, Nikolaus S, Frings N, and Schreiber S. Heritability of chronic venous disease. Hum Genet 2010; 127(6): 669-674.
9. Wali MA and Eid RA. Intimal changes in varicose veins: an ultrastructural study. J Smooth Muscle Res 2002; 38(3): 63-74.
10. Wali MA and Eid RA. Changes of elastic and collagen fibers in varicose veins. Int Angiol 2002; 21(4): 337-343.
11. Wali MA, Dewan M, and Eid RA. Histopathological changes in the wall of varicose veins. Int Angiol 2003; 22(2): 188-193.
12. Porto LC, Ferreira MA, Costa AM, and da Silveira PR. Immunolabeling of type IV collagen, laminin, and alpha-smooth muscle actin cells in the intima of normal and varicose saphenous veins. Angiology 1998; 49(5): 391-398.
13. Tovar AM, de Mattos DA, Stelling MP, Sarcinelli-Luz BS, Nazareth RA, and Mourao PA. Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II. Biochim Biophys Acta 2005; 1740(1): 45-53.
14. He L, Giri TK, Vicente CP, and Tollefsen DM. Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II. Blood 2008; 111(8): 4118-4125.
15. Yla-Herttuala S, Sumuvuori H, Karkola K, Mottonen M, and Nikkari T. Glycosaminoglycans in normal and atherosclerotic human coronary arteries. Lab Invest 1986; 54(4): 402-407.
16. Merrilees MJ, Beaumont B, and Scott LJ. Comparison of deposits of versican, biglycan and decorin in saphenous vein and internal thoracic, radial and coronary arteries: correlation to patency. Coron Artery Dis 2001; 12(1): 7-16.
17. Sisto T, Yla-Herttuala S, Luoma J, Riekkinen H, and Nikkari T. Biochemical composition of human internal mammary artery and saphenous vein. J Vasc Surg 1990; 11(3): 418-422.
18. Marquezini MV, Strunz CM, Dallan LA, and Toledo OM. Glycosaminoglycan distribution in atherosclerotic saphenous vein grafts. Cardiology 1995; 86(2): 143-146.
19. Wolanska M, Sobolewski K, Glowinski S, Kowalewski R, and Plonski A. Glycosaminoglycans of normal veins and their alterations in varicose veins and varicose veins complicated by thrombophlebitis. Eur Surg Res 2001; 33 (1): 28-32.
20. Leta GC, Mourao PA, and Tovar AM. Human venous and arterial glycosaminoglycans have similar affinity for plasma low-density lipoproteins. Biochim Biophys Acta 2002; 1586(3): 243-253.
21. Sansilvestri-Morel P, Nonotte I, Fournet-Bourguignon MP, Rupin A, Fabiani JN, Verbeuren TJ, and Vanhoutte PM. Abnormal deposition of extracellular matrix proteins by cultured smooth muscle cells from human varicose veins. J Vasc Res 1998; 35(2): 115-123.
22. Sansilvestri-Morel P, Rupin A, Badier-Commander C, Kern P, Fabiani JN, Verbeuren TJ, and Vanhoutte PM. Imbalance in the synthesis of collagen type I and collagen type III in smooth muscle cells derived from human varicose veins. J Vasc Res 2001; 38(6): 560-568.
23. Sansilvestri-Morel P, Rupin A, Badier-Commander C, Fabiani JN, and Verbeuren TJ. Chronic venous insufficiency: dysregulation of collagen synthesis. Angiology 2003; 54 Suppl 1: S13-S18.
24. Takase S, Pascarella L, Lerond L, Bergan JJ, and Schmid-Schonbein GW. Venous hypertension, inflammation and valve remodeling. Eur J Vasc Endovasc Surg 2004; 28(5): 484-493.
25. Kirsch D, Schreiber J, Dienes HP, Bottger T, and Junginger T. Alterations of the extracellular matrix of venous walls in varicous veins. Vasa 1999; 28(2): 95-99.
26. Mannello F, Jung K, Tonti GA, and Canestrari F. Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood. Clin Biochem 2008; 41(18): 1466-1473.
27. Mannello F. Serum or plasma samples? The "Cinderella" role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation. Arterioscler Thromb Vasc Biol 2008; 28(4): 611-614.
28. Hu J, Van den Steen PE, Sang QX, and Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6(6): 480-498.
29. Moali C and Hulmes DJ. Extracellular and cell surface proteases in wound healing: new players are still emerging. Eur J Dermatol 2009; 19(6): 552-564.
30. Mannello F and Gazzanelli G. Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis 2001; 6(6): 479-482.
31. Mannello F, Luchetti F, Falcieri E, and Papa S. Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 2005; 10(1): 19-24.
32. Murphy G and Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008; 29(5): 290-308.
33. Knauper V and Murphy G. Methods for studying activation of matrix metalloproteinases. Methods Mol Biol 2010; 622: 233-243.
34. Lim CS and Davies AH. Pathogenesis of primary varicose veins. Br J Surg 2009; 96(11): 1231-1242.
35. Papazafiropoulou A and Tentolouris N. Matrix metalloproteinases and cardiovascular diseases. Hippokratia 2009; 13(2): 76-82.
36. Simka M. Cellular and molecular mechanisms of venous leg ulcers development--the "puzzle" theory. Int Angiol 2010; 29(1): 1-19.
37. Tarlton JF, Bailey AJ, Crawford E, Jones D, Moore K, and Harding KD. Prognostic value of markers of collagen remodeling in venous ulcers. Wound Repair Regen 1999; 7(5): 347-355.
38. Raffetto JD and Khalil RA. Matrix metalloproteinases in venous tissue remodeling and varicose vein formation. Curr Vasc Pharmacol 2008; 6(3): 158-172.
39. Jacob MP, Badier-Commander C, Fontaine V, Benazzoug Y, Feldman L, and Michel JB. Extracellular matrix remodeling in the vascular wall. Pathol Biol (Paris) 2001; 49(4): 326-332.
40. Soini Y, Satta J, Maatta M, and utio-Harmainen H. Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart. J Pathol 2001; 194(2): 225-231.
41. Raffetto JD, Barros YV, Wells AK, and Khalil RA. MMP-2 induced vein relaxation via inhibition of [Ca2+]e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides. J Surg Res 2010; 159(2): 755-764.
42. Badier-Commander C, Verbeuren T, Lebard C, Michel JB, and Jacob MP. Increased TIMP/ MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation. J Pathol 2000; 192(1): 105-112.
43. Peschen M. Cytokines in progressing stages of chronic venous insufficiency. Curr Probl Dermatol 1999; 27: 13-19.
44. Saito S, Trovato MJ, You R, Lal BK, Fasehun F, Padberg FT, Jr., Hobson RW, Duran WN, and Pappas PJ. Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency. J Vasc Surg 2001; 34(5): 930-938.
45. Zamboni P, Scapoli G, Lanzara V, Izzo M, Fortini P, Legnaro R, Palazzo A, Tognazzo S, and Gemmati D. Serum iron and matrix metalloproteinase-9 variations in limbs affected by chronic venous disease and venous leg ulcers. Dermatol Surg 2005; 31(6): 644-649.
46. Mwaura B, Mahendran B, Hynes N, Defreitas D, Avalos G, Adegbola T, Adham M, Connolly CE, and Sultan S. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers. Eur J Vasc Endovasc Surg 2006; 31(3): 306-310.
47. Ulrich D, Lichtenegger F, Unglaub F, Smeets R, and Pallua N. Effect of chronic wound exudates and MMP-2/-9 inhibitor on angiogenesis in vitro. Plast Reconstr Surg 2005; 116(2): 539-545.
48. Subramaniam K, Pech CM, Stacey MC, and Wallace HJ. Induction of MMP-1, MMP-3 and TIMP-1 in normal dermal fibroblasts by chronic venous leg ulcer wound fluid*. Int Wound J 2008; 5(1): 79-86.
49. Yager DR, Zhang LY, Liang HX, Diegelmann RF, and Cohen IK. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Invest Dermatol 1996; 107(5): 743-748.
50. Baker EA and Leaper DJ. Proteinases, their inhibitors, and cytokine profiles in acute wound fluid. Wound Repair Regen 2000; 8(5): 392-398.
51. Muller M, Trocme C, Lardy B, Morel F, Halimi S, and Benhamou PY. Matrix metalloproteinases and diabetic foot ulcers: the ratio of MMP-1 to TIMP-1 is a predictor of wound healing. Diabet Med 2008; 25(4): 419-426.
52. Rayment EA, Upton Z, and Shooter GK. Increased matrix metalloproteinase-9 (MMP-9) activity observed in chronic wound fluid is related to the clinical severity of the ulcer. Br J Dermatol 2008; 158(5): 951-961.
53. Cook H, Davies KJ, Harding KG, and Thomas DW. Defective extracellular matrix reorganization by chronic wound fibroblasts is associated with alterations in TIMP-1, TIMP-2, and MMP-2 activity. J Invest Dermatol 2000; 115 (2): 225-233.
54. Schultz GS and Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen 2009; 17(2): 153-162.
55. Liu Y, Min D, Bolton T, Nube V, Twigg SM, Yue DK, and McLennan SV. Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers. Diabetes Care 2009; 32(1): 117-119.
56. Toriseva M and Kahari VM. Proteinases in cutaneous wound healing. Cell Mol Life Sci 2009; 66(2): 203-224.
57. Mirastschijski U, Schnabel R, Claes J, Schneider W, Agren MS, Haaksma C, and Tomasek JJ. Matrix metalloproteinase inhibition delays wound healing and blocks the latent transforming growth factor-beta1-promoted myofibroblast formation and function. Wound Repair Regen 2010; 18(2): 223-234.
58. Utz ER, Elster EA, Tadaki DK, Gage F, Perdue PW, Forsberg JA, Stojadinovic A, Hawksworth JS, and Brown TS. Metalloproteinase expression is associated with traumatic wound failure. J Surg Res 2010; 159(2): 633-639.
59. Raffetto JD and Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75(2): 346-359.
60. Jacob SS, Shastry P, and Sudhakaran PR. Monocyte-macrophage differentiation in vitro: modulation by extracellular matrix protein substratum. Mol Cell Biochem 2002; 233(1-2): 9-17.
61. Johnson JL, Jackson CL, Angelini GD, and George SJ. Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 1998; 18(11): 1707-1715.
62. Herouy Y, Nockowski P, Schopf E, and Norgauer J. Lipodermatosclerosis and the significance of proteolytic remodeling in the pathogenesis of venous ulceration (Review). Int J Mol Med 1999; 3(5): 511-515.
63. Zamboni P. The big idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis. J R Soc Med 2006; 99(11): 589-593.
64. Kowalewski R, Sobolewski K, Malkowski A, Wolanska M, and Gacko M. Evaluation of enzymes involved in proteoglycan degradation in the wall of abdominal aortic aneurysms. J Vasc Res 2006; 43(1): 95-100.
65. Ra HJ and Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol 2007; 26(8): 587-596.
66. Sluijter JP, de Kleijn DP, and Pasterkamp G. Vascular remodeling and protease inhibition--bench to bedside. Cardiovasc Res 2006; 69 (3): 595-603.
67. Lim CS, Shalhoub J, Gohel MS, Shepherd AC, and Davies AH. Matrix metalloproteinases in vascular disease--a potential therapeutic target? Curr Vasc Pharmacol 2010; 8(1): 75-85.
68. Hobeika MJ, Thompson RW, Muhs BE, Brooks PC, and Gagne PJ. Matrix metalloproteinases in peripheral vascular disease. J Vasc Surg 2007; 45(4): 849-857.
69. Trowbridge JM and Gallo RL. Dermatan sulfate: new functions from an old glycosaminoglycan. Glycobiology 2002; 12(9): 117R 125R.
70. Malavaki C, Mizumoto S, Karamanos N, and Sugahara K. Recent advances in the structural study of functional chondroitin sulfate and dermatan sulfate in health and disease. Connect Tissue Res 2008; 49(3): 133-139.
71. Tersariol IL, Pimenta DC, Chagas JR, and Almeida PC. Proteinase activity regulation by glycosaminoglycans. Braz J Med Biol Res 2002; 35(2): 135-144.
72. Isnard N, Robert L, and Renard G. Effect of sulfated GAGs on the expression and activation of MMP-2 and MMP-9 in corneal and dermal explant cultures. Cell Biol Int 2003; 27(9): 779-784.
73. Yu WH, Yu S, Meng Q, Brew K, and Woessner JF, Jr. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 2000; 275(40): 31226-31232.
74. Mannello F, Tonti GA, Medda V, and Raffetto JD. In vitro inhibition of MMP-9 forms by glycosaminoglycan Sulodexide. A new direction for therapeutic applications involving chronic inflammatory conditions. Clin Biochem 2010; in press
75. Scondotto G, Aloisi D, Ferrari P, and Martini L. Treatment of venous leg ulcers with sulodexide. Angiology 1999; 50(11): 883-889.
76. Coccheri S, Scondotto G, Agnelli G, Palazzini E, and Zamboni V. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebocontrolled study. Eur Heart J 2002; 23(13): 1057-1065.
77. Coccheri S, Scondotto G, Agnelli G, Aloisi D, Palazzini E, and Zamboni V. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost 2002; 87(6): 947-952.
78. Ofosu FA. Pharmacological actions of sulodexide. Semin Thromb Hemost 1998; 24(2): 127-138.
79. Lauver DA, Booth EA, White AJ, Poradosu E, and Lucchesi BR. Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis. J Pharmacol Exp Ther 2005; 312(2): 794-800.
80. Lauver DA and Lucchesi BR. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev 2006; 24(3-4): 214-226.
81. Mannello F, Tonti G, and Papa S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Targets 2005; 5(4): 285-298.
82. Mannello F. Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon? Recent Pat Anticancer Drug Discov 2006; 1(1): 91-103.